Luciano J. Costa, MD, PhD

Articles

Navigating the Current Landscape of Relapsed/Refractory Multiple Myeloma

July 11th 2025

Panelists discuss how the evolving treatment landscape, including CAR T-cell therapy and bispecifics, has made it possible to offer cellular therapies like cilta-cel as early as second-line treatment for eligible patients.

Real-World Decision-Making: Triplet vs Quadruplet in NDMM-TI

July 11th 2025

Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Emerging Data in Transplant-Ineligible NDMM: DREAMM-10, ENDURANCE, and CC-220-MM-001

July 4th 2025

Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Targeted Insights: IMROZ Trial and the Role of 1q21+  and MRD/PET-CT

July 4th 2025

Panelists discuss how isatuximab-containing quadruplet regimens offer clinical benefit in patients with 1q gain or amplification, though its advantage appears to reflect a class effect among CD38-targeting agents.

CEPHEUS Subgroup Analyses: Insights From ASCO 2025

June 27th 2025

Panelists analyses from the CEPHEUS suggest that quadruplet regimens provide broad benefits in transplant-ineligible patients, though ultra–high-risk subtypes may require novel strategies discuss how subgroup.

Management Approaches and Unmet Needs in Transplant-Ineligible NDMM

June 27th 2025

Panelists discuss how treating newly diagnosed, transplant-ineligible multiple myeloma patients requires a nuanced approach that accounts for comorbidities, age, and functional status to optimize induction therapy.

ASCO 2025: Updates From PERSEUS, ADVANCE, and Other Trials in Transplant-Eligible NDMM

June 20th 2025

Panelists discuss how data from the PERSEUS trial supports the use of daratumumab in quadruplet regimens to improve sustained minimal residual disease negativity and progression-free survival in transplant-eligible myeloma patients.

Managing Transplant-Eligible NDMM: Current Treatments

June 20th 2025

Panelists discuss how quadruplet-based induction therapy, including anti-CD38 monoclonal antibodies, is becoming the preferred frontline treatment for transplant-eligible patients with multiple myeloma based on risk stratification.

Dr Costa on the Clinical Implications of the MASTER Trial in Multiple Myeloma

September 11th 2023

Luciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.

Dr Costa on the Background of the MASTER Trial in Newly Diagnosed Multiple Myeloma

August 1st 2023

Luciano J. Costa, MD, PhD, discusses the background of the phase 2 MASTER trial in newly diagnosed multiple myeloma.

Dr Costa on MRD-Modulated Post-ASCT Quadruplet Induction in Newly Diagnosed Multiple Myeloma

June 21st 2023

Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.

Relapsed/Refractory Multiple Myeloma: Future Directions in Care

June 16th 2022

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.

Moving Bispecific and CAR T-Cell Therapies to Earlier Lines of Therapy in MM

June 16th 2022

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

Multiple Myeloma: Sequencing Novel Bispecific and CAR T-Cell Therapies

June 9th 2022

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma

June 9th 2022

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

Patient Scenario 2: A 57-Year-Old With Heavily Pretreated MM

June 2nd 2022

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

MajesTEC-1: Teclistamab in Relapsed or Refractory Multiple Myeloma

June 2nd 2022

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

May 26th 2022

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

May 26th 2022

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Dr. Costa on Developing Later-Line Therapies for the Frontline Setting in Multiple Myeloma

April 28th 2021

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.